Discover
DRUG
Bright Minds Biosciences Inc.
54.05
1 x 55.10
1 x 55.40
bid
ask
+
2.05
3.94%
1 @ 04:00 PM
54.05 +0.00 (0.00%)
| Ytd | -30.74% | |
| 1y | -11.99% |
51.91
day range
55.78
48.25
52 week range
95.99
| Open | 51.91 | Prev Close | 52.00 | Low | 51.91 | High | 55.78 | Mkt Cap | 533.15M |
| Vol | 98.41K | Avg Vol | 159.01K | EPS | -2.05 | P/E | N/A | Forward P/E | N/A |
| Beta | 1.13 | Short Ratio | 0.70 | Inst. Own | 44.28% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-17 | 50-d Avg | 67.35 | 200-d Avg | 75.82 | 1yr Est | 4.87 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-08-14 | 2024-06 | 0 | 0.04 | N/A | N/A |
| 2024-05-15 | 2024-03 | 0 | -0.1 | N/A | N/A |
| 2024-02-12 | 2023-12 | 0 | -0.32 | N/A | N/A |
| 2023-12-29 | 2023-09 | 0 | -0.3 | N/A | N/A |
| 2010-08-06 | 2010-06 | 0 | N/A | N/A | N/A |
| 2010-05-17 | 2010-03 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-25 | Baird | Upgrade | Outperform |
Profile
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2022-08-23 | Fryzuk (Jeremy) | Director of Issuer | 30.00K | Acquisition or disposition in the public market |
| 2021-12-29 | Kozikowski Alan P | 10% Security Holder of Issuer | 2.00M | Acquisition or disposition in the public market |
| 2021-12-14 | McDonald (Ian) | Director of Issuer | 914.90K | Acquisition or disposition in the public market |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | AdvisorShares Investments, LLC | 182.42K | 7.06M | 2.63% |
| 2024-09-29 | National Bank of Canada/FI | 4.96K | 191.86K | 0.07% |
| 2024-09-29 | UBS Group AG | 3.41K | 131.82K | 0.05% |
| 2024-09-29 | Royal Bank of Canada | 660.00 | 25.54K | 0.01% |
| 2024-09-29 | Aspire Private Capital, LLC | 100.00 | 3.87K | 0.00% |
| 2024-09-29 | Blackrock Inc. | 1.00 | 38.00 | 0.00% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | AdvisorShares Trust-AdvisorShares Psychedelics ETF | 297.00 | 11.49K | 0.00% |
Split
| Split | Date |
|---|---|
| 1 : 5 | 2023-07-14 |